Loading startup
Market data is refreshed once per day from public sources. Information may be incomplete or outdated — verify independently before making decisions. This is not investment advice.
Evidence-bound summary — expand sections for movement, risks, and signals.
Memo snapshot · May 20, 2026, 6:08 PM
DealFlow OS uses public web data and automated enrichment. Research may be incomplete, outdated, or incorrect. Verify important information before making investment or outreach decisions.
TL;DR
Seed (YC)Exin Therapeutics
Raised $500K across 1 funding round. Latest: $500K Pre-seed (Jan 2025). Investors: Y Combinator. (High).
Funding
Raised $500K across 1 funding round. Latest: $500K Pre-seed (Jan 2025). Investors: Y Combinator. (High).
Hiring
1 hiring‑related row(s); role‑spam risk if mostly generic boards (Low).
Product / news
3 product/news‑styled row(s); headline risk without filings (High).
Verified facts
+2 more in Recent movement below
Winter 2025 batch; AI drug discovery for neurotherapeutics using in-house mouse studies and multimodal ML.
Weak funding evidence: mention does not include a parsed raise amount/round and may refer to non-funding context.
No open roles indexed yet.
The index price and activity score are algorithmic estimates based on observed public company-level signals. They may be incomplete, stale, or inaccurate and are not investment, legal, tax, or business advice.
Source types found
Strongest / recent news-style rows
News · Thu, Jul 2, 03:37 PM · confidence 90%high quality
Wed, May 20, 06:08 PM · confidence 88%high quality
Wed, May 20, 06:08 PM · confidence 85%medium quality
Newest first · 6 event(s)
Source: News
13th Jan. 2025. - Exin Therapeutics officially launches!
Source: Blog
Lowering the cost of data, raising the scale of discovery.
Source: Careers page
We are hiring the lab team for our new R&D facility in Metro Manila, Philippines. The Manila lab will be the cornerstone of our experimental efforts, enabling ultra large-scale in vivo neuroscience and data generation to power the discovery of novel neurother…
Source: Homepage
We are developing a target discovery platform for neurotherapeutics targeting neural circuits - across disorders.
Winter 2025 batch; AI drug discovery for neurotherapeutics using in-house mouse studies and multimodal ML.
Launch post on circuit-level approach and multimodal AI for preclinical R&D.
1 row(s)
The company's own site — the authoritative description of what they sell and to whom. Marketing-controlled, so treat claims as positioning rather than verified traction.
We are developing a target discovery platform for neurotherapeutics targeting neural circuits - across disorders.
Why it matters: Primary source — the company's own positioning; best read for what they sell and to whom, not for traction claims.
Open source ↗2 row(s)
Third-party press coverage. Independent reporting corroborates company claims; repeated coverage across outlets is a momentum signal.
13th Jan. 2025. - Exin Therapeutics officially launches!
Why it matters: Independent coverage — third-party corroboration of company claims; recurring coverage indicates rising visibility.
Open source ↗Launch post on circuit-level approach and multimodal AI for preclinical R&D.
Why it matters: Independent coverage — third-party corroboration of company claims; recurring coverage indicates rising visibility.
Open source ↗1 row(s)
Funding announcements and investor-database records. The strongest public signal of capitalization: round, amount, and syndicate quality when disclosed.
Winter 2025 batch; AI drug discovery for neurotherapeutics using in-house mouse studies and multimodal ML.
Why it matters: Funding signal — Pre-Seed per this source; verify against the linked original before relying on it.
Open source ↗1 row(s)
Open roles and careers pages. Active hiring implies runway to spend and shows where the company is investing (engineering vs GTM vs ops).
We are hiring the lab team for our new R&D facility in Metro Manila, Philippines. The Manila lab will be the cornerstone of our experimental efforts, enabling ultra large-scale in vivo neuroscience and data generation to power the discovery of novel neurother…
Why it matters: Hiring signal — open roles imply runway to spend and show where the company is investing.
Open source ↗1 row(s)
Company blog and newsletters. Shipping cadence and technical depth of posts hint at product velocity and team quality.
Lowering the cost of data, raising the scale of discovery.
Why it matters: Company publishing — post cadence and depth hint at product velocity.
Open source ↗Sign in as an active team member to view private notes, watchlist controls, transcript evidence, and interaction history.